Healthcare biotechnology in India |
| |
Authors: | L M Srivastava |
| |
Institution: | (1) Department of Biochemistry, Sir Ganga Ram Hospital, Rajinder Nagar, 110 060 New Delhi |
| |
Abstract: | Summary Biotechnology in India has made great progress in the development of infrastructure, manpower, research and development and
manufacturing of biological reagents, biodiagnostics, biotherapeutics, therapeutic and, prophylactic vaccines and biodevices.
Many of these indigenous biological reagents, biodiagnostics, therapeutic and prophylactic vaccines and biodevices have been
commercialized. Commercially when biotechnology revenue has reached $25 billions in the U.S. alone in 2000 excluding the revenues
of biotech companies that were acquired by pharmaceutical companies, India has yet to register a measurable success. The conservative
nature and craze of the Indian Industry for marketing imported biotechnology products, lack of Government support, almost
non-existing national healthcare system and lack of trained managers for marketing biological and new products seem to be
the important factors responsible for poor economic development of biotechnology in India. With the liberalization of Indian
economy, more and more imported biotechnology products will enter into the Indian market. The conditions of internal development
of biotechnology are not likely to improve in the near future and it is destined to grow only very slowly. Even today biotechnology
in India may be called to be in its infancy. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|